The UK’s net-zero agenda places significant demands on the housing and local authority sectors to drastically reduce carbon emissions across existing and new homes.
With decarbonisation high on the agenda—and DESNZ funding available through the Warm Homes programmes—TIAA plays a critical role in translating policy and grants into real-world impact: supporting organisations to manage funding effectively for cleaner, healthier, and future-proof housing.
DESNZ Grant Funding: The Warm Homes Programmes
The Department for Energy Security & Net Zero (DESNZ) offers substantial grant funding to tackle housing emissions:
- Warm Homes: Social Housing Fund (formerly Social Housing Decarbonisation Fund)
- Wave 3 launched Sept 2024 with £1.29 billion, supporting delivery from 2025–2028.
- Offers up to £7,500 per home, and up to £20,000 for off-grid properties installing low‑carbon heating. [wslaw.co.uk], [socialhousing.co.uk], [insidehousing.co.uk]
- Warm Homes: Local Grant
- Allocates around £500 million to local authorities and private/low-income homeowners for insulation, heat pumps, solar installations, targeting ~270 councils over 3 years. [housingdigital.co.uk]
- Additional £1.8 billion funding through other schemes supports insulating homes and decarbonising public sector buildings. [gov.uk], [housingdigital.co.uk]
How TIAA Supports Organisations with Grant Claims
TIAA assists housing providers, local authorities, and organisations in navigating the grants landscape and maximising funding claims for decarbonisation projects:
- Strategic funding support
TIAA guides clients through grant criteria, such as reaching EPC Band C, fabric-first upgrades, and low-carbon heating eligibility. - Implementation support
Beyond securing funds, TIAA provides project oversight—ensuring procurement, delivery, reporting, and compliance across grant timelines. - Claim management & auditing
TIAA ensures proper documentation, evidence, and financial claims to help organisations fully access available grant funding without leaving money unclaimed.